Language:

Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations

Nature reviews. Drug discovery, 2016-04, Vol.15 (4), p.235-247 [Peer Reviewed Journal]

COPYRIGHT 2016 Nature Publishing Group ;Copyright Nature Publishing Group Apr 2016 ;ISSN: 1474-1776 ;EISSN: 1474-1784 ;DOI: 10.1038/nrd.2015.35 ;PMID: 26965203

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations
Author: Hoos, Axel
Subjects: Analysis ; Antibodies, Monoclonal - pharmacology ; Antineoplastic Agents - pharmacology ; Cancer ; Care and treatment ; Cellular therapy ; CTLA-4 Antigen - immunology ; Humans ; Immunity - drug effects ; Immunotherapy ; Immunotherapy - methods ; Immunotherapy - trends ; Ipilimumab ; Medication Therapy Management - trends ; Neoplasms - drug therapy ; Neoplasms - immunology ; Programmed Cell Death 1 Receptor - immunology ; Treatment Outcome
Is Part Of: Nature reviews. Drug discovery, 2016-04, Vol.15 (4), p.235-247
Description: Since the regulatory approval of ipilimumab in 2011, the field of cancer immunotherapy has been experiencing a renaissance. This success is based on progress in both preclinical and clinical science, including the development of new methods of investigation. Immuno-oncology has become a sub-specialty within oncology owing to its unique science and its potential for substantial and long-term clinical benefit. Immunotherapy agents do not directly attack the tumour but instead mobilize the immune system - this can be achieved through various approaches that utilize adaptive or innate immunity. Therefore, immuno-oncology drug development encompasses a broad range of agents, including antibodies, peptides, proteins, small molecules, adjuvants, cytokines, oncolytic viruses, bi-specific molecules and cellular therapies. This Perspective summarizes the recent history of cancer immunotherapy, including the factors that led to its success, provides an overview of novel drug-development considerations, summarizes three generations of immunotherapies that have been developed since 2011 and, thus, illustrates the breadth of opportunities these new generations of immunotherapies represent.
Publisher: England: Nature Publishing Group
Language: English
Identifier: ISSN: 1474-1776
EISSN: 1474-1784
DOI: 10.1038/nrd.2015.35
PMID: 26965203
Source: MEDLINE
ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations

COPYRIGHT 2016 Nature Publishing Group ;Copyright Nature Publishing Group Apr 2016 ;ISSN: 1474-1776 ;EISSN: 1474-1784 ;DOI: 10.1038/nrd.2015.35 ;PMID: 26965203

Searching Remote Databases, Please Wait